Business
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting
ROCKVILLE, Md., April 15, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through
About this update from Regenxbio Inc.
[{"type":"text","content":"ROCKVILLE, Md., April 15, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the presentation of four posters at the American Society of Gene & Cell Therapy (ASGCT) 2019 Annual Meeting in Washington, D.C., from April 29 to May 2, 2019.\nThe data will be presented as follows:\nAbstract Title: Determination of AAV Genome Content and Capsid Content by Size Exclusion Chromatography (abstract #184)Presenter: Brian Howie, Associate Scientist, REGENXBIOSession Title: AAV VectorsDate/Time: Monday, April 29, 2019, 5:00 p.m. to 6:00 p.m. ETLocation: Columbia Hall\nAbstract Title: Assessing Purity and Structures of AAV Vector Genomes by High Performance Size Exclusion Chromatography (abstract #174)Presenter: Li Zhi, Ph.D., Senior Scientist, REGENXBIOSession Title: AAV VectorsDate/Time: Monday, April 29, 2019, 5:00 p.m. to 6:00 p.m. ETLocation: Columbia Hall\nAbstract Title: Structure-Guided Engineering of Surface-Exposed Loops on the AAV Capsid (abstract #466)Presenter: Samantha Yost, Ph.D., Scientist I, REGENXBIOSession Title: AAV Vectors IIDate/Time: Tuesday, April 30, 2019, 5:00 p.m. to 6:00 p.m. ETLocation: Columbia Hall\nAbstract Title: Validation of AAV Transgene-Specific Quantification Assay Using BioRad Droplet Digital PCR (abstract #734)Presenter: Scott Jenkins, Associate Scientist II, REGENXBIOSession Title: AAV Vectors IIIDate/Time: Wednesday, May 1, 2019, 5:00 p.m. to 6:00 p.m. ETLocation: Columbia Hall\nAbout REGENXBIO Inc.\nREGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.\nContacts:\nInvestors:Heather Savelle, [email protected]\nMedia:David Rosen, [email protected]\n \n\n\n\n View original content to download multimedia:ht...